Franz Thomas Walt
Franz Thomas Walt (*1959, Switzerland) holds a Master of Business Administration of City University, Bellevue, Washington as well as a Management Diploma of IMAKA, Zurich.
Following his studies, Mr. Walt spent over 30 years in management positions at two of the world’s largest healthcare companies, Siemens Healthineers and Roche. Between 1989 and 2011 he held various management positions at Roche, most recently as Chairman of the Board of Management at Roche Diagnostics GmbH, Mannheim, as well as Regional President Roche Diabetes Care and Head of the EMEA and Latin America Regions. After Roche, he worked for Siemens Healthineers AG between 2012 and 2017, most recently as President Laboratory Diagnostics. Since 2018, he has been Chief Executive Officer of NASDAQ-listed Quotient Ltd. Flims, Switzerland.
Mr. Walt has been a member of the Supervisory Board of Epigenomics AG since May 2019. The current term ends in 2021. He is an independent member (within the meaning of the German Corporate Governance Code).
Mr. Walt is not a member of other mandatory supervisory boards or comparable boards with supervisory function.